

# Juan M. Hincapie-Castillo, PharmD, MS, PhD

Curriculum Vitae (Updated on May 5, 2022)

Email: [JHincapie-Castillo@unc.edu](mailto:JHincapie-Castillo@unc.edu)

Business Phone: +1 (919) 966-7421

Website: <https://www.DrJuanHC.com>

2101F McGavran-Greenberg Hall, CB #7435

Chapel Hill, NC 27599-7435

## CURRENT POSITION

---

### Assistant Professor

Department of Epidemiology

Gillings School of Global Public Health, University of North Carolina at Chapel Hill

### Faculty Affiliations:

2021 – Present Center for Pharmacoepidemiology, University of North Carolina at Chapel Hill

2021 – Present Injury Prevention Research Center, University of North Carolina at Chapel Hill

### Other Affiliations:

2021 – Present Center for Public Health Law Research, Temple University  
Research Fellow

2019 – Present University of Florida, Department of Pharmaceutical Outcomes & Policy  
Graduate Faculty Status

## EDUCATION

---

2021 – Present **Master of Jurisprudence (M.J.)**  
Loyola University Chicago – Chicago, IL  
**Concentration:** Health Law

2019 **Doctor of Philosophy (Ph.D.)** in Pharmaceutical Sciences  
University of Florida – Gainesville, FL  
**Concentration:** Pharmacoepidemiology  
**Dissertation:** Evaluating unintended consequences of strategies aimed to control the opioid crisis on acute pain management patient outcomes

2017 **Master of Science (M.S.)** in Pharmacy  
University of Florida – Gainesville, FL  
**Concentration:** Pharmaceutical Outcomes & Policy  
**Master Thesis:** Prevalence of psychotherapy surrounding initiation of psychotropic medication polypharmacy in the Medicaid-insured population

2013 **Doctor of Pharmacy (Pharm.D.)** – *Cum Laude*  
University of Florida – Jacksonville, FL

2009 **Associate in Arts** (Pre-pharmacy studies) – *High Honors*  
Florida State College at Jacksonville – Jacksonville, FL

## EMPLOYMENT

---

January 2022 – Present	<b>Pharmacist - Medication Therapy Management</b> AspenRx Health (Hourly)
August 2021 – Present	<b>Assistant Professor (tenure-track)</b> University of North Carolina at Chapel Hill, Gillings School of Global Public Health Department of Epidemiology
July 2020 – Present	<b>Special Government Employee</b> Consultant - Drug Safety and Risk Management Advisory Board (DSaRM) FDA Center for Drug Evaluation and Research (CDER)
August 2019 – August 2021	<b>Assistant Professor (tenure-track)</b> University of Florida College of Pharmacy Department of Pharmaceutical Outcomes and Policy
May 2019 – August 2019	<b>Provisional Assistant Professor</b> University of Florida College of Pharmacy Department of Pharmaceutical Outcomes and Policy
August 2013 – May 2019	<b>Graduate Research Assistant</b> University of Florida College of Pharmacy Department of Pharmaceutical Outcomes and Policy
August 2015 – August 2016	<b>Clinical Expert (EHR chart reviewer)</b> University of Florida College of Medicine Division of Hematology/Oncology
May 2011 – August 2011	<b>Research Intern (Pharmacoepidemiology)</b> University of Florida College of Pharmacy Department of Pharmaceutical Outcomes and Policy

## HONORS AND AWARDS

---

### Faculty

2022	<b>Kenneth Rothman Travel Award</b> – Society for Epidemiologic Research
2022	<b>Junior Faculty Development Award</b> – UNC Office of Executive Vice-Chancellor and Provost
2021	<b>Research Fellow</b> – Center for Public Health Law Research, Temple University
2020	<b>Teaching Service Incentive Award</b> – UF College of Pharmacy
2020	<b>Faculty Role Model Award</b> – Comprehensive Cancer Research Training Opportunities for Outstanding Leaders (ReTOOL) Program
2020	<b>Keynote Speaker</b> – UF College of Pharmacy Doctoral & Master's Commencement Summer 2020
2020	<b>2020 Emerging Leader Award</b> – International Society for Pharmacoepidemiology
2020	<b>New Investigator Award</b> – American Association of Colleges of Pharmacy
2019	<b>"Rising Stars in Health Sciences"</b> Symposium for Underrepresented Minority Researchers
2019	<b>2018 Best Reviewer</b> – Pharmacoepidemiology and Drug Safety Journal

### Graduate Studies

2019	<b>Third-Best Student Abstract</b> – 35 <sup>th</sup> International Conference on Pharmacoepidemiology
2019	<b>Travel grant</b> – 35 <sup>th</sup> International Conference on Pharmacoepidemiology. Philadelphia, USA
2017	<b>Deborah Klapp Memorial Award</b> – UF College of Pharmacy
2017	<b>Travel grant</b> – 2017 ISPE Mid-Year Meeting. London, UK

2017	<b>Levitt Division Finalist</b> – 30 <sup>th</sup> Research Showcase. UF College of Pharmacy
2016	<b>DuBow Family Graduate Student Education Fellowship</b> – UF College of Pharmacy
2016	<b>Best overall presentation</b> – 34 <sup>th</sup> Annual Pediatric Science Day – UF Department of Pediatrics
2016	<b>Travel grant</b> – 32 <sup>st</sup> International Conference on Pharmacoepidemiology. Dublin, Ireland
2016	<b>Teaching Assistant of the Year Award</b> – UF Graduating PharmD Class of 2016
2016	<b>Graduate Student Teaching Award</b> – University of Florida Graduate School
2015	<b>Travel grant</b> – 31 <sup>st</sup> International Conference on Pharmacoepidemiology. Boston, USA
2015	<b>Graduate Fellow</b> – American Association of Hispanics in Higher Education (AAHHE)
2013	<b>International Pharmacy Service Award</b> – UF College of Pharmacy
2013	<b>Student Leadership Award</b> - UF Graduating PharmD Class of 2013 (Jacksonville)
2013	<b>Outstanding Service Award</b> – UF Graduating PharmD Class of 2013 (Jacksonville)
2013	<b>Phi Lambda Sigma Chapter Member of the Year</b> – Phi Lambda Sigma - Iota Chapter
2013	<b>Dean’s Honor Roll</b> – UF College of Pharmacy
2012	<b>Leadership Training Series Certificate</b> APhA- Academy of Student Pharmacists
2012	<b>Paul Magalian Scholarship</b> – FSHP Research and Education Foundation
2012	<b>Outstanding Phi Lambda Sigma Member</b> – UF College of Pharmacy (Jacksonville)
2012	<b>Most Valuable Pharm.D. (MVP) Award</b> – Faculty of College of Pharmacy (Jacksonville)
2012	<b>CVS/Pharmacy Scholarship</b> – UF College of Pharmacy
2012	<b>Debbie DeSantis Scholarship</b> – UF College of Pharmacy
2011	<b>Jack Eckerd Fund Scholarship</b> – UF College of Pharmacy
2011, 2010	<b>NEFSHP First Coast Pharmacy Scholarship Award</b>

## GRANTS AND RESEARCH SUPPORT

---

### CURRENT

- **Evaluating the Impact of State Laws Restricting Opioid Prescriptions on Acute Pain Management in Medicare Beneficiaries (Junior Faculty Development Award)**

- Role: PI (10% In-Kind) 01/01/2022-12/31/2022
- Funded for \$10,000 by UNC Office of Executive Vice-Chancellor and Provost

This project aims to quantify the effects of state opioid restriction laws on opioid use among Medicare enrollees. Using Medicare prescription claims data for 2011-2019, we will conduct drug utilization analyses to evaluate the following monthly measures for acute pain patient populations

- **Evaluation of utilization patterns of cough medications in the United States**

- Role: MPI (7.5%) 06/01/2021-12/31/2022 (Co-PI: Lo-Ciganic)
- Funded for \$275,829 by Merck Sharp & Dohme Corp

The goal of the study is to (1) estimate changes in the trend in chronic cough medication (CCM) use over time in the US ambulatory care settings, and (2) to identify and characterize the distinct CCM utilization trajectories and associated factors using Medicare and OneFlorida data.

### COMPLETED

- **Evaluation of drug treatment for incident trigeminal neuralgia in Medicare-insured patients**

- Role: PI (10% In-kind) 09/01/2020 – 8/31/2021
- Funded for \$25,000 total direct costs by UF Center for Advancing Minority Pain and Aging Science (Subaward of P30AG059297 by National Institute on Aging)

This study aims to describe the initial drug treatment for trigeminal neuralgia in older adults using real-world data and to understand the patient characteristics associated with individual treatment selection.

- **Leveraging social media data for evaluation of drug use trends after opioid policies (ACCP New Investigator Award)**
  - Role: PI (10% In-kind) 03/01/2020 – 02/28/2021
  - Funded for \$10,000 by American Association of Colleges of Pharmacy (ACCP)

The proposed study aims at exploring the feasibility of using consumer-generated data from social media to evaluate trends in prescription and illicit opioid use in the context of opioid-related policies.

- **Developing a real-time trajectory tool to identify potentially unsafe concurrent opioid and benzodiazepine use among older adults (1R21AG060308-01A1)**
  - Role: Co-Investigator (2.5%) 02/01/2020 – 01/31/2021 (PI: Lo-Ciganic)
  - Funded for \$308,206 in total direct costs by National Institute on Aging (NIA)

The proposed study aims at developing an innovative, real-time “Predicting Risky Opioid-Benzodiazepine Trajectory e-Care Tool (PROTeCT)” for efficiently identifying and predicting subgroups of older adults (aged ≥50 years) with distinct and potentially unsafe patterns of opioid and benzodiazepine use.

- **Consortium for Medical Marijuana Clinical Outcomes Research**
  - Role: Co-Investigator (20%) 07/25/2019 – 06/30/2020 (PI: Winterstein)
  - Funded for \$1,500,000 by the State University System of Florida (Direct state appropriation)

Faculty lead for the Medical Marijuana Clinical Outcomes Research Repository (MEMORY). This state appropriation establishes the consortium for medical marijuana clinical outcomes research, charged to generate and disseminate evidence on the outcomes of the medical use of marijuana to inform clinical and policy decisions.

- **Enhancing active learning of a root cause analysis on a medication error in the patient safety and quality in pharmacy course**
  - Role: Co-Investigator (5% In-kind) 06/01/2019 – 12/31/2019 (PI: Vouri)
  - Funded for \$15,000 by the UF College of Pharmacy PROSPER Teaching Innovation Award

This funding was used for the development of a series of immersive video vignettes to teach concepts of medication error in the PharmD curriculum. We used a multi-pronged approach for evaluating learning outcomes and attitudes towards medication errors.

- **Evaluating changes in Order Sets for inpatient Pain Management (EOS-PM)**
  - Role: Co-Investigator (70%) 01/01/2016 – 06/30/2016 (PI: Winterstein)
  - Funded for \$27,826 by the UF Health Shands Endowment Fund

This study evaluated the effectiveness and safety of newly implemented explicit opioid titration protocols at UF Health Shands.

#### **SUBMITTED (Pending or not funded)**

- **Evaluating unanticipated consequences of opioid prescribing restriction laws to inform policy implementation strategies and improve care quality in Medicaid (1R03HS028080-01)**
  - Role: MPI (10%) Council review pending (Co-PI: Goodin)
  - Impact score: 30
  - \$100,000 total, over 1 year. Agency for Healthcare Research and Quality (AHRQ)

This study aims to compare prescribing policy restriction-severity outcomes by evaluating changes in opioid use and health services utilization among Medicaid beneficiaries.

## PUBLICATIONS

---

**ORCID:** 0000-0002-6945-2713 **Scopus ID:** 56205625300 **Web of Science ResearcherID:** J-5499-2019

My NCBI Bibliography: <https://www.ncbi.nlm.nih.gov/myncbi/1JOlcJfON8fQo/bibliography/public/>

Google Scholar: <https://scholar.google.com/citations?user=TT2g4C0AAAAJ&hl=en>

Keys to indicate author relationship: self=**bold**; senior/corresponding author=underline

\* First author is a graduate student, post-doc, or fellow for whom I was the primary mentor

### REFEREED JOURNAL ARTICLES

1. \* Keshwani S, Maguire M, Goodin A, Lo-Ciganic W, Wilson D, **Hincapie-Castillo JM**. Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in Two State Medicaid Programs. *JAMA Health Forum*. 2022 (*In Press*)
2. Park H, Desai R, Liu X, Smith SM, **Hincapie-Castillo J**, Henry L, Goodin A, Gopal S, Pepine CJ, Mohandas R: Medicare bundled payment policy on anemia care, major adverse cardiovascular events, and mortality among adults undergoing hemodialysis. *Clin J Am Soc Nephrol*. 2022 (*In Press*)
3. Shen Y, **Hincapie-Castillo JM**, Vouri S, Dewar M, Sumfest J, Goodin A. Prescription Patterns of Adjuvant Pain Medications Following Opioid Supply Restriction Law in Florida: An Interrupted Time Series Analysis. *Medical Care*. 2022. doi: 10.1097/MLR.0000000000001719
4. Lo-Ciganic W, **Hincapie-Castillo JM**, Wang T, Ge Y, Jones B, Huang J, Chang CY, Wilson D, Lee JK, Reisfield G, Kwoh C, Delcher C, Nguyen K, Zhou L, Shorr R, Guo J, Marcum Z, Harle C, Park H, Winterstein A, Yang S, Huang P, Adkins L, Gellad W. Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: Group-based multi-trajectory models. *Addiction*. 2022;10.1111/add.15857
5. Yang S, Orlova Y, Lipe A, Boren M, **Hincapie-Castillo JM**, Park H, Chang C, Wilson D, Adkins L, Lo-Ciganic W. Trends in the Management of Primary Headaches in US Emergency Departments: Analysis of 2007-2018 National Hospital Ambulatory Medical Care Survey Data. *J Clin Med* 2022; 11(5): 1401
6. Unigwe I, Yang S, Song HJ, Lo-Ciganic W, **Hincapie-Castillo JM**, Cook R, Park H. Trends in sexually transmitted infections in the United States ambulatory care clinics from 2005-2016. *J Clin Med*. 2021;11(1):71
7. Oueini R, Goodin A, **Hincapie-Castillo JM**, Vouri S. Co-utilization of opioids and non-benzodiazepine hypnotic drugs in U.S. ambulatory care visits, 2006-2016. *J Am Pharm Assoc*. 2021;S1544-3191(21)00438-6
8. Shen Y, **Hincapie-Castillo JM**, Vouri S, Dewar M, Sumfest J, Goodin A. Chronic Opioid Therapy Utilization Following an Acute Pain Prescription Supply Restriction Law: An Interrupted Time Series Analysis. *Pain Physician* 2021;24(6):417-424
9. Valdes I, Possinger M, **Hincapie-Castillo JM**, Goodin A, Dewar M, Sumfest J, Vouri SM. Changes in Prescribing by Provider Type Following a State Prescription Opioid Restriction Law. *J Gen Intern Med*. 2021;10.1007/s11606-021-06966-4
10. \* Keshwani S, Grande I, Maguire M, Vouri S, Goodin A, **Hincapie-Castillo JM**. The effects of the Florida's Opioid Restriction Law for Acute Pain on the Utilization of Prescription NSAID Medications. *JAMA Netw Open*. 2021;4(6):e2113383

11. Goodin A, **Hincapie-Castillo JM**, Brown J, Roussos-Ross K. A Survey Assessment of Clinician Perceptions of Opioid Supply and Monitoring Requirement Policy Changes. *J Opioid Manag*. 2021;17(4):337-342
12. \* Oueini R, Goodin A, Vouri SM, Lo-Ciganic W, Park H, **Hincapie-Castillo JM**. Changes in Schedule II Oral Opioid Volume Dispensed in a Private Payer Following Florida's Acute Pain Opioid Restriction Law. *J Manag Care Spec Pharm*. 2021;27(6):779-784
13. Tran PT, Atonelli P, **Hincapie-Castillo JM**, Winterstein A. Effects of Food and Drug Administration Removal of Indications for Use of Oral Quinolones. *JAMA Intern Med*. 2021;181(6):808-816
14. Albogami Y, Sarayani A, **Hincapie-Castillo JM**, Winterstein AG. Real-World Fetal Exposure to Acne Treatments in the United States: A Retrospective Analysis from 2006 to 2015. *Drug Saf*. 2021;44(4):447-454
15. Jugl S, Okpeku A, Costales B, Morris E, Alipour-Haris G, **Hincapie-Castillo JM**, Stetten N, Sajdeya R, Keshwani S, Joseph V, Zhang Y, Shen Y, Adkins L, Goodin A. A mapping literature review of medical cannabis clinical outcomes and quality of evidence in approved conditions in the United States from 2016 to 2019. *Med Cannabis Cannabinoids*. 2021;4(1):21-42
16. **Hincapie-Castillo JM**, Easey T, Hernandez C, Goodin A, Usmani S, Vouri S. Changes in Quantity of Opioids Dispensed Following Florida's Restriction Law for Acute Pain Prescriptions. *Pain Med*. 2021;22(8):1870-1876
17. Hong Y, Xie Z, Gutter M, Odedina F, **Hincapie-Castillo JM**. Purchasing Drugs Abroad among US Cancer Survivors: Analysis of National Health Interview Survey 2011-2018. *Am J Prev Med*. 2021;60(5):e231-e234
18. Shen Y, Bhagwandass H, Branchcomb T, Galvez S, Grande I, Lessing J, Mollanazar M, Ourhaan N, Oueini R, Sasser M, Valdes I, Jadubans A, Hollman J, Maguire M, Usmani S, Vouri S, **Hincapie-Castillo JM**, Adkins L, Goodin A. Chronic Opioid Therapy: A Scoping Literature Review on Evolving Clinical and Scientific Definitions. *J Pain*. 2021;22(3):246-262
19. Usmani S, Hollman J, Adkins A, Ourhaan N, Oueini R, Bhagwandass H, Goodin A, **Hincapie-Castillo JM**, Vouri S. Effects of Hydrocodone Rescheduling on Opioid Prescribing Outcomes: Systematic Review. *J Am Pharm Assoc*. 2021;61(2):e20-e44
20. \* Brokenshire S, Lemon SJ, Staley B, Voils A, **Hincapie-Castillo JM**. Impact of Injectable Opioid Restrictions during a Critical Drug Shortage Period: Interrupted Time Series for Institutional Opioid Utilization. *Pain Med*. 2021;22(1):203-211
21. Hong Y, **Hincapie-Castillo JM**, Xie Z, Segal S, Mainous A. Socioeconomic and Demographic Characteristics of Americans who purchase Prescription Drugs Outside the United States. *JAMA Netw Open*. 2020;3(6):e208968
22. **Hincapie-Castillo JM**, Goodin A, Possinger M, Usmani S, Vouri S. Changes in Opioid Use After Florida's Restriction Law for Acute Pain Prescriptions. *JAMA Netw Open*. 2020;3(2):e200234
23. Sarayani A, Albogami Y, Elkhider M, **Hincapie-Castillo JM**, Brumback B, Winterstein AG. Comparative Effectiveness of Risk Mitigation Strategies to Prevent Fetal Exposure to Mycophenolate. *BMJ Qual Saf*. 2020;29(8):636-644
24. **Hincapie-Castillo JM**, Henriksen C, Staley B, Saidi A, Lipori G, Winterstein AG. Development of a Predictive Model for Drug-induced QT Prolongation in the Inpatient Setting Using EHR Data. *Am J Health Syst Pharm*. 2019; 76(14):1059-1070

25. Soria-Saucedo R, Liu X, **Hincapie-Castillo JM**, Zambrano D, Bussing R, Winterstein AG. Prevalence, time trends and utilization patterns of psychotropic polypharmacy: Evidence from children and adolescent Medicaid beneficiaries, 1999-2010. *Psychiatr Serv*. 2018; 69(8):919-926
26. Winterstein AG, Staley B, Henriksen C, Xu D, Lipori G, Jeon N, Choi Y, Li Y, **Hincapie-Castillo JM**, Soria-Saucedo R, Brumback B, Johns T. Development and validation of a Complexity-Score to rank hospitalized patients at risk for preventable adverse drug events. *Am J Health Syst Pharm*. 2017; 74(23):1970-1984
  - **2018 Pharmacy Practice Research Literature Award from the ASHP Foundation**
27. Liu X, Hatton R, **Hincapie-Castillo JM**, Zhu Y, Bussing R, Barnicoat M, Winterstein AG. Consistency of psychotropic drug–drug interactions listed in drug monographs. *J Am Pharm Assoc*. 2017; 57(6):698-703.e2
28. **Hincapie-Castillo JM**, Liu X, Bussing R, Winterstein AG. Prevalence of psychotherapy surrounding initiation of psychotropic medication polypharmacy in the Medicaid-insured population, 1999-2010. *Psychiatr Serv*. 2017; 68(11):1120-1126
29. Jeon N, Staley B, Klinker KP, **Hincapie-Castillo JM**, Winterstein AG. Acute Kidney Injury Risk Associated with Piperacillin-Tazobactam compared with Cefepime during Vancomycin Therapy in Hospitalized Patients: Cohort Study stratified by Baseline Kidney Function. *Int J Antimicrob Agents*. 2017; 50(1):63-67.
30. Moorman-Li R, Gilbert B, Orman A, Aldridge P, Leger-Krall S, Anderson C, **Hincapie-Castillo JM**. Evaluating the effects of diffused lavender in an Adult Day Care Center for patients with dementia in an effort to decrease behavioral issues: A Pilot Study. *J Drug Assess*. 2017; 6(1):1-5
31. Witenko C, Moorman-Li R, Motycka C, Duane K, **Hincapie-Castillo JM**, Leonard P, Valaer C. Considerations for the Appropriate Use of Skeletal Muscle Relaxants for the Management of Acute Low Back Pain. *P T*. 2014; 39(6):427-435
32. Winterstein AG, **Hincapie-Castillo JM**, Xu D, Liu W, Antonelli PJ. Otological Neomycin Exposure in Children with Non-Intact Tympanic Membranes. *Laryngoscope*. 2012; 122:2529-2532

## LETTERS TO THE EDITOR

1. **Hincapie-Castillo JM**, Nicholson K, Baker T. Re: Reducing health disparities through achieving pharmacoequity. *JAMA*. 2022;327(6):589-590
2. Goodin A, **Hincapie-Castillo JM**. A call to look beyond prescription opioid supply-side restrictions and include health equity when predicting opioid policy effectiveness. *Lancet Reg Health Am*. 2021; 3: 100075. doi.org/10.1016/j.lana.2021.100075
3. **Hincapie-Castillo JM**, Wei J, Winterstein AG. Clinical utility and perils of prescription drug monitoring program-based alert systems. *PAIN*. 2018; 159(4):804-805
4. **Hincapie-Castillo JM**, Daniels PF. Use of lithium in patients with unipolar depression. *Lancet Psychiatry*. 2017; 4(9):662
5. Choi Y, **Hincapie-Castillo JM**. Bariatric surgery and risk for perinatal complications. *JAMA Surg*. 2017; 152(6):607-608

## BOOK CHAPTERS

1. Lo-Ciganic W, **Hincapie-Castillo JM**. *Chapter 20: Systematic Reviews and Meta-Analysis in Pharmacy*. In Aparasu R, Bentley J, Pate A. Student Handbook for Pharmacy Practice Research. McGraw-Hill Companies, INC. 2021 (*In Press*)
2. Moorman-Li R, **Hincapie-Castillo JM**. *Chapter 31: Pain management Medication Therapy Management Data Set*. In Whalen K and Hardin H. Medication Therapy Management: A pharmacotherapy and Medication System Primer. McGraw-Hill Companies, INC. 2018
3. Moorman-Li R, McLin K, **Hincapie-Castillo JM**. *Chapter 31: Pain management Medication Therapy Management Data Set*. In Angaran DM and Whalen K. Medication Therapy Management: A pharmacotherapy and Medication System Primer. McGraw-Hill Companies, INC. 2015

## PEER-REVIEWED ABSTRACTS (Publications and Conference Presentations)

1. \* Keshwani S, Goodin A, Lo-Ciganic W, **Hincapie-Castillo JM**. Buprenorphine Use Trends Following Prior Authorization Policy Change for Opioid Use Disorder Treatment in Two State Medicaid Programs, from 2013 to 2020. (*In Press, Poster presentation accepted at virtual 2021 Addiction Health Services Research Conference*)
2. Ravindra N, Faddoul N, Lo-Ciganic W, **Hincapie-Castillo JM**, Park H, Heldermon CD, Yang S, Wilson DL, Adkins L, **Chang C**. Association Between Non-Adherence to Endocrine Therapy and the Risk of Recurrence Among Breast Cancer Survivors: A Systematic Literature Review. *Pharmacoepidemiol Drug Saf.* 2021;30(Suppl. 1):148-149 (*Poster at Virtual 37<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk*)
3. Faddoul N, Ravindra N, Lo-Ciganic W, **Hincapie-Castillo JM**, Park H, Heldermon CD, Yang S, Wilson DL, Adkins L, **Chang C**. Opioid Use Patterns Among Non-Metastatic Cancer Survivors: A Systematic Literature Review. *Pharmacoepidemiol Drug Saf.* 2021;30(Suppl. 1):285 (*Poster at Virtual 37<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk*)
4. Oueini R, **Hincapie-Castillo JM**, Goodin A, **Vouri S**. Co-utilization of Opioids and Non-Benzodiazepine Sedative Hypnotics in U.S. Ambulatory Care Visits, 2006 – 2016. *Pharmacoepidemiol Drug Saf.* 2021;30(Suppl. 1):100-101 (*Poster at Virtual 37<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk*)
5. Yang S, Lipe A, Boren M, **Hincapie-Castillo JM**, Brown J, Guo J, Park H, Chang C, Wilson DL, Adkins L, Lo-Ciganic W. Trends in the Management of Primary Headache in US Emergency Departments: Analysis of 2007-2018 U.S. National Hospital Ambulatory Medical Care Survey Data. *Pharmacoepidemiol Drug Saf.* 2021;30(Suppl. 1):378 (*Poster at Virtual 37<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk*)
6. \* Keshwani S, Brown J, Lo-Ciganic W, Yang S, Smolinski N, **Hincapie-Castillo JM**. Trends in Prescribing of Non-Steroidal Anti-Inflammatory Medications in the US Ambulatory Care Setting, 2006-2016. *Pharmacoepidemiol Drug Saf.* 2021;30(Suppl. 1):377-378 (*Poster at Virtual 37<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk*)
7. **Hincapie-Castillo JM**, Goodin A, Allen J, Grundman O, Cavanaugh T. A spatiotemporal evaluation of community pharmacy practice experience site placement within diverse patient communities (2016-2020). (*In press, Accepted poster presentation at the 2020 American Association for Colleges of Pharmacy Virtual Annual Meeting*)



8. \* Ourhaan N, Bhagwandass H, Goodin A, **Hincapie-Castillo JM**. Trends in Utilization of Amphetamine-Containing Medications Following State Level Restriction Laws for Acute Pain Opioid Prescriptions. Value in Health. 2021; 24:S89-S90 (**Poster Presentation at the 2021 ISPOR Virtual Conference**)
  - **Top 5 Student Abstract**
9. \* Staret J, Goodin A, Bhagwandass H, **Hincapie-Castillo JM**. Changes in Schedule II Opioid Prescriptions Dispensed by Medicaid in Following Acute Pain Opioid Restriction Laws. Value in Health. 2021; 24:S149 (**Poster Presentation at the 2021 ISPOR Virtual Conference**)
10. \* Easey T, Vouri SM, Goodin A, **Hincapie-Castillo JM**, Impact of State Laws Restricting Opioid Prescriptions for Acute Pain on Opioid-Related Overdose Deaths Assessed Via Interrupted Time Series Analyses. Value in Health. 2021; 24:S132-S133 (**Poster Presentation at the 2021 ISPOR Virtual Conference**)
11. Yang S, Boren M, Lipe A, **Hincapie-Castillo JM**, Joshua DB, Park H, Guo J, Chang C, Wilson DL, Adkins EL, Lo-Ciganic W. Trends and Characteristics in Opioid Analgesic Use for Migraine in US Emergency Departments: Analysis of National Hospital Ambulatory Medical Care Survey 2007-2018 Data. Value in Health. 2021; 24:S168 (**Poster Presentation at the 2021 ISPOR Virtual Conference**)
12. Ravindra N, Faddoul N, Lo-Ciganic W, **Hincapie-Castillo JM**, Park H, Heldermon CD, Yang S, Wilson DL, Adkins L, Chang C. Association Between Non-adherence to Endocrine Therapy and the Risk of Recurrence among Breast Cancer Survivors: A Systematic Literature Review. Value in Health. 2021; 24:S62 (**Poster Presentation at the 2021 ISPOR Virtual Conference**)
13. Goodin AJ, **Hincapie-Castillo JM**, Maguire M, Okpeku A, Min J, AG Winterstein. Enhancing Prediction of All-Cause 30-Day Inpatient Psychiatric Facility Readmissions Using Electronic Health Record-Derived Data. (**In press, Accepted poster presentation at Academy Health 2021 Annual Research Meeting**)
14. \* Keshwani S, Grande I, Maguire M, Vouri S, Goodin A, **Hincapie-Castillo JM**. The effects of the Florida's Opioid Restriction Law for Acute Pain on the Utilization of Prescription NSAID Medications. (**In press, Accepted poster presentation at virtual 2020 American Academy of Pain Medicine Annual Meeting**)
15. Oueini R, **Hincapie-Castillo JM**, Vouri SM. Co-utilization of Opioids and Non-Benzodiazepine Sedative Hypnotics in US Ambulatory Care Visits, 2006–2016. (**Published in conference proceedings; Poster presentation at the 2020 American College of Clinical Pharmacy Annual Meeting**)
16. \* Easey T, Smith K, Chirino A, Hernandez C, Moorman-Li R, Goodin A, Vouri S, **Hincapie-Castillo JM**. Comparing the Current Status of State Laws of Opioid Prescribing Restrictions in the United States. Addict Sci Clin Pract 2020, 15(Suppl 2):A91 (**Poster presentation at virtual 2019 Addiction Health Services Research Conference**)
17. Valdes I, Possinger M, **Hincapie-Castillo JM**, Goodin A, Dewar M, Sumfest J, Vouri S. Changes in Opioid Utilization by Provider Type Following a Days' Supply Restriction Policy. Addict Sci Clin Pract 2020, 15(Suppl 2):A90 (**Poster presentation at virtual 2019 Addiction Health Services Research Conference**)
18. Shen Y, Bhagwandass H, Branchcomb T, Galvez S, Grande I, Hollmann J, Lessing J, Mollanazar M, Ourhaan N, Oueini R, Sasser M, Valdes I, Jadubans A, Vouri S, **Hincapie-Castillo JM**, Adkins L, Goodin A. Chronic Opioid Therapy: A Scoping Literature Review on Evolving Clinical and Scientific Definitions. Addict Sci Clin Pract 2020, 15(Suppl 2):A113 (**Poster presentation at virtual 2019 Addiction Health Services Research Conference**)
19. Shen Y, **Hincapie-Castillo JM**, Vouri S, Dewar M, Sumfest J, Goodin A. Prescription Patterns of Adjuvant Medications Following Opioid Supply Restriction Law in Florida: An Interrupted Time Series Analysis. Addict Sci Clin Pract 2020, 15(Suppl 2):A12 (**Poster presentation at virtual 2019 Addiction Health Services Research Conference**)

- **Top Rated Abstract**

20. **Hincapie-Castillo JM**, Goodin A, Tadrus M, Dal Pan G. Methods to Evaluate the Effects of Policy Changes During the Opioid Crisis. *Pharmacoepidemiol Drug Saf.* 2020;29(Suppl. 3):153 (***Symposium at Virtual 36<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk***)
21. **Lo-Ciganic W**, Wang T, Ge Y, Jones B, Huang J, Reisfield G, Lee J, Kwoh K, **Hincapie-Castillo JM**, Delcher C, Chang CY, Wilson D, Gellad W. Association between Dose and Duration Patterns of Opioid and Benzodiazepine Use and Risk of Overdose Among US Medicare Beneficiaries: A Group-Based Multi-Trajectory Model. *Pharmacoepidemiol Drug Saf.* 2020;29(Suppl. 3):5 (***Oral presentation at Virtual 36<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management***)
22. Chang C, **Hincapie-Castillo JM**, Wilson DL, **Lo-Ciganic W** Trends and Patient Characteristics in Concurrent Use of Opioids with High-risk Medications among Arizona Medicaid Beneficiaries, 2011-2017. *Pharmacoepidemiol Drug Saf.* 2020;29(Suppl. 3):274 (***Poster presentation at Virtual 36<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management***)
23. Yang S, **Hincapie-Castillo JM**, Chang C, Wilson DL, **Lo-Ciganic W**. Trends and Characteristics in Cough Prescription Use in Ambulatory Care Settings in the United States: 2003-2016. *Pharmacoepidemiol Drug Saf.* 2020;29(Suppl. 3):253 (***Poster presentation at Virtual 36<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management***)
24. Tran P, Antonelli P, **Hincapie-Castillo JM**, **Winterstein A**. Impact of the Food and Drug Administration Safety Warnings and Removal of Indications for Use of Oral Quinolones. *Pharmacoepidemiol Drug Saf.* 2020;29(Suppl. 3):151-152 (***Oral presentation at Virtual 36<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management***)
25. Goodin A, Huang J, Park H, **Hincapie-Castillo JM**, Brown J, Costales B<sub>(g)</sub>, Wilson D, **Lo-Ciganic W**. Changes in Prevalence of High-Risk Opioid Use Quality Measures in Arizona, 2011-2018. (***Published in conference proceedings; Poster presentation at the 2020 Virtual Annual Research Meeting of AcademyHealth***)
26. Jugl S, Okpeku A Costales B, Morris E, Alipour-Harris G, **Hincapie-Castillo JM**, Stetten N, Sajdeya R, Keshwani S, Joseph V, Zhang Y, Shen Y, Adkins L, **Goodin A**. A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the United States from 2016 to 2019. *Cannabis.* 2021, 4(1), 15-16 (***Poster presentation at the 2020 Research Society of Marijuana virtual meeting***)
27. **Hincapie-Castillo JM**, Unigwe I, Goodin A, Vouri S. Enhancing Active Learning of Root Cause Analysis: An Immersive Medication Error Experience from Multiple Perspectives. *American Journal of Pharmaceutical Education.* 2020; 84(6). (***Poster presentation at the 2020 American Association for Colleges of Pharmacy Virtual Annual Meeting***)
28. **Goodin A**, **Hincapie-Castillo JM**, Vouri S. Pragmatic Model for PharmD Student Engagement in Social and Administrative Pharmacy Research: UF Research Workgroup. *American Journal of Pharmaceutical Education.* 2020; 84(6). (***Poster presentation at the 2020 American Association for Colleges of Pharmacy Virtual Annual Meeting***)
29. \* Tasmim K, Goodin A, Lopez-Quintero C, Park H, Mora J, Lo-Ciganic W, **Hincapie-Castillo JM**. Increases in County-Level Opioid Prescribing in the United States despite National Declining Rates, 2012-2017. (***Published in conference proceedings; Poster presentation at the 2020 Virtual Scientific Meeting of the College on Problems of Drug Dependence***)

30. **Hincapie-Castillo JM**, Goodin A, Vouri S, Lo-Ciganic W, Park H. PDG33 Changes in Schedule II Oral Opioid Volume Dispensed in a Private Payer Following Florida's Acute Pain Opioid Restriction Law. *Value in Health*. 2020; 23:S135 (**Poster presentation at the 2020 ISPOR Virtual Conference**)
31. **Lo-Ciganic W**, Wang T, Ge Y, Jones B, Huang J, Reisfield GM, Lee JK, Kwok CK, **Hincapie-Castillo JM**, Delcher C, Chang CY, Wilson D, Gellad. WPMH26 Association between Dose and Duration Patterns of Opioid and Benzodiazepine Use and Risk of Overdose Among US Medicare Beneficiaries: A Group-Based Multi-Trajectory Model. *Value in Health*. 2020; 23:S204-S205 (**Poster Presentation at the 2020 ISPOR Virtual Conference**)
32. Chang C-Y, **Hincapie-Castillo JM**, Wilson DL, **Lo-Ciganic W**. Evaluation of concurrent use of opioids with high-risk medications among Arizona Medicaid beneficiaries: cross-sectional analysis from 2011 to 2017. *Pharmacoepidemiol Drug Saf*. 2020;29(Suppl. 3):643 (**Poster presentation at the 2020 Mid-Year ISPE meeting [canceled due to COVID-19]**)
33. Shen Y, Vouri S, **Hincapie-Castillo JM**, **Goodin A**. Prescription Opioid Patterns Following Supply Restriction Policy among Patients Receiving Chronic Opioid Therapy: An Interrupted Time Series Analysis. *Pharmacoepidemiol Drug Saf*. 2020;29(Suppl. 3):647 (**Poster presentation at the 2020 Mid-Year ISPE meeting [canceled due to COVID-19]**)
34. Lemon S, Brokenshire S, Staley B, Voils A, **Hincapie-Castillo JM**. 119: Impact of Injectable Opioid Restrictions on Opioid Consumption during a Critical Drug Shortage. *Crit Care Med*. 2020 Jan;48(1):42. (**Poster presentation at the 2020 Critical Care Congress, Orlando, FL**)
35. **Hincapie-Castillo JM**, Goodin A, Silken U, Possinger M, Vouri S. Changes in Opioid Utilization Following Florida's Acute Pain Restriction Policy. In: Garets M, Archer S, Kitchens C, Cochran G, Gordon AJ. The 2019 Addiction Health Services Research Conference: Insights, review, and abstracts. *Subst Abus*. 2019;40(4):469-472 (Supp 113) (**Podium presentation 2019 Addiction Health Services Research Conference, Park City, UT**)
36. Goodin A, Huang J, Park H, Skvarla D, **Hincapie-Castillo JM**, **Lo-Ciganic W**. Controlled Substance Prescription Utilization Trends in Arizona from 2011-2016, by Prescription Class. In: Garets M, Archer S, Kitchens C, Cochran G, Gordon AJ. The 2019 Addiction Health Services Research Conference: Insights, review, and abstracts. *Subst Abus*. 2019;40(4):469-472 (Supp 113). (**Podium presentation at 2019 Addiction Health Services Research Conference, Park City, UT**)
37. Usmani S, Hollmann J, Ourhaan N, Oueini R, Bhagwandass H, Goodin A, **Hincapie-Castillo JM**, **Vouri S**. Effects of Hydrocodone Rescheduling on Opioid Prescribing Outcomes: A Systematic Review. In: Garets M, Archer S, Kitchens C, Cochran G, Gordon AJ. The 2019 Addiction Health Services Research Conference: Insights, review, and abstracts. *Subst Abus*. 2019;40(4):469-472 (Supp 113). (**Poster presentation at 2019 Addiction Health Services Research Conference, Park City, UT**)
38. **Hincapie-Castillo JM**, Antonelli P, **Winterstein AG**. Use of Joinpoint regression in drug utilization research: Post-tonsillectomy codeine use in pediatrics, United States (2005-2016). *Pharmacoepidemiol Drug Saf*. 2019; 28(Suppl. 2):250-251. (**Poster presentation at the 35<sup>th</sup> International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA**)
  - **Third-Best Abstract Submitted by Student/Postdoc Award Winner**
39. Sarayani A, Albogami Y, Elkhider M, **Hincapie-Castillo JM**, Brumback B, **Winterstein AG**. Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate. *Pharmacoepidemiol Drug Saf*. 2019; 28(Suppl. 2):222. (**Podium presentation at the 35<sup>th</sup> International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA**)

40. **Hincapie-Castillo JM**, Guo Y, Silver NL, Xiao H. Spatial analysis of late-stage oropharyngeal cancer diagnosis in Florida: Hierarchical models and geographically-weighted regression. *Cancer Res* 2018;78(13 Suppl):Abstract number 1202. **(Poster presentation at 2018 American Association of Cancer Research Annual Meeting, Chicago, IL)**
41. Liu, X, **Hincapie-Castillo JM**, Zhu Y, Bussing R, Winterstein AG. Prevalence of Concomitant Use of Psychotropic Drugs with Severe or Major Drug-Drug Interactions in Children and Adults with Psychotropic Therapy. *Pharmacoepi Drug Saf* 2017; 26(Suppl. 2):334. **(Poster presentation at 33<sup>rd</sup> International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Montreal, CA)**
42. **Hincapie-Castillo JM**, Smith A. Abstract Selection Process for the 2017 International Society for Pharmacoepidemiology Midyear Meeting *Pharmacoepi Drug Saf* 2017; 26(Suppl. 2):492. **(Poster presentation at 33<sup>rd</sup> International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Montreal, CA)**
43. **Hincapie-Castillo JM**, Staley B, Henriksen C, Lipori G, Winterstein AG. Development of a Predictive Model for Uncontrolled Post-Operative Pain in the Inpatient Setting Using Electronic Health Record Data. **(Published in conference proceedings; Podium presentation at the 2017 Mid-Year ISPE meeting, London, UK)**
44. **Hincapie-Castillo JM**, Henriksen C, Staley B, Saidi A, Lipori G, Winterstein AG Development of a Predictive Model for Drug-induced QT Prolongation in the Inpatient Setting Using Electronic Health Record Data. *Pharmacoepi Drug Saf* 2016; 25(Suppl. 3):492. **(Podium presentation at 32<sup>nd</sup> International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, IE)**
45. Soria-Saucedo R, Liu X, **Hincapie-Castillo JM**, Winterstein AG. Prevalence, Time Trends and Utilization Patterns of Psychotropic Polypharmacy: Evidence from Children and Adolescent Medicaid Beneficiaries, 1999-2010. *Pharmacoepi Drug Saf* 2016; 25(Suppl. 3):668. **(Poster presentation at 32<sup>nd</sup> International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, IE)**
46. Soria-Saucedo R, Liu X, **Hincapie-Castillo JM**, Winterstein AG. Prevalence, Time Trends and Utilization Patterns of Psychotropic Polypharmacy: Evidence from Adult Medicaid Beneficiaries, 1999-2010. *Pharmacoepi Drug Saf* 2016; 25(Suppl. 3):668. **(Poster presentation at 32<sup>nd</sup> International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, IE)**
47. Soria-Saucedo R, Liu X, **Hincapie-Castillo J**, Bussing R, Winterstein AG. Prevalence, time trends and utilization patterns of psychotropic polypharmacy: Evidence from children and adolescent Medicaid beneficiaries, 1999-2010. **(Published in conference proceedings, Poster presentation at the 2016 Annual Research Meeting Academy Health, Boston, MA)**
48. Bussing R, Liu X, **Hincapie-Castillo JM**, Winterstein AG. Psychotropic Polypharmacy Patterns in Medicaid Recipients: Trends and Concerns. **(Published in conference proceedings, Poster presentation at the 2015 Annual Meeting of American Academy of Child and Adolescent Psychiatry, San Antonio, TX)**
49. Knox CA, **Hincapie-Castillo JM**, Winterstein AG. Validity of Delivery Outcomes Within the Medicaid Analytic eXtract (MAX) Database. *Pharmacoepi Drug Saf* 2015; 24:14. **(Podium presentation at 31<sup>st</sup> International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA)**
50. **Hincapie-Castillo JM**. Prescription Drug Monitoring Program and Drug Arrests in Florida: Spatial Analysis. *Pharmacoepi Drug Saf* 2015; 24:69. **(Poster presentation at 31<sup>st</sup> International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA)**

51. Winterstein AG, **Hincapie-Castillo JM**, Xu D, Liu W, Antonelli PJ. Otological Neomycin Exposure in Children with Non-Intact Tympanic Membranes. (*Published in conference proceedings, Poster presentation at the 2012 American Laryngological Rhinological and Otological Society, Miami, FL*)

## DISSERTATION / THESIS

- **Hincapie-Castillo JM**. Evaluating Unintended Consequences of Strategies Aimed to Control the Opioid Crisis on Acute Pain Management Patient Outcomes. Doctoral Dissertation. University of Florida, 2019
- **Hincapie-Castillo JM**. Prevalence of psychotherapy surrounding initiation of psychotropic medication polypharmacy in the Medicaid-insured population, 1999-2010. Master Thesis. University of Florida, 2017

## REPORTS

- **Hincapie-Castillo JM**, Maguire M, Okpeku A, Min J, Goodin A. All-cause readmission measure of an inpatient psychiatry facility using electronic health record data. Report to UF Health and UF College of Pharmacy, 2020
- **Hincapie-Castillo JM**, Winterstein AG. Evaluating Changes in Order Sets for inpatient Pain Management (EOS-PM). Report to UF Health and UF College of Pharmacy, 2018
- Winterstein AG, Liu X, **Hincapie-Castillo JM**, Bussing R. Psychotropic polypharmacy in Florida Medicaid. Report to the Agency for Healthcare Administration, 2015

## REFEREED JOURNAL ARTICLES, SUBMITTED OR IN PROGRESS

- **Hincapie-Castillo JM**, Goodin A. Using Joinpoint Regression for Drug Utilization Research: Tutorial and Case Study of Prescription Opioid Use in the United States. (Under Review)
- **Hincapie-Castillo JM**, Goodin A, Freeman P. Putting Patients First: Pharmacists' Professional Obligations within the Prescription Opioid Ecosystem. (Under Review)
- **Hincapie-Castillo JM**, Unigwe I, Goodin A, Vouri S. Enhancing Active Learning of Medication Errors in the PharmD Curriculum through a Multi-perspective Experience. (Under Review)
- Jang HR, Quinones-Marrero J, **Hincapie-Castillo JM**. Are the kids alright? Environmental scan of current COVID-19 infection dashboards in the Florida public school system. (Under Review)
- Yang S, **Hincapie-Castillo JM**, Ke X, Schelfhout J, Ding H, Sher M, Zhou L, Chang C, Wilson D, Lo-Ciganic W. Evaluation of Patterns of Cough Medication Use in Ambulatory Care Settings in the United States: 2003-2018. (Under Review)
- **Hincapie-Castillo JM**, Joseph M, Branchcomb T, Maguire M, Wilkerson J, Allen J, Cavanaugh T, Grundman O, Goodin A, A spatiotemporal evaluation of community introductory and advanced pharmacy practice experience site placements within diverse patient communities (2016-2020) (In preparation)
- **Hincapie-Castillo JM**, Deravi M, Vouri S, Goodin A. Pragmatic Model for PharmD Student Engagement in Social and Administrative Pharmacy Research: UF Research Workgroup. (In preparation)

## NON-REFEREED PUBLICATIONS

1. **Juan M. Hincapie-Castillo**: Opioid prescription limits have unintended consequences. Gainesville Sun, The (FL). March 2, 2020.

## PROFESSIONAL ACTIVITIES

---

### Editorial Boards

- 2021 – Present     **Pharmacoepidemiology and Drug Safety**  
Associate Editor – Americas Editorial Office
- 2021 – Present     **Journal of the American Pharmacists Association**  
Editorial Advisory Board Member

**Ad hoc reviewer for professional journals** (Number of Manuscripts) **Publons ID: 1538093** ([Profile link](#))

- American Journal of Health-System Pharmacy** (15)  
**Pain Medicine** (6)  
**Pharmacoepidemiology & Drug Safety** (6)
- Best Reviewer 2018
- Journal of the American Pharmacists Association** (6)
- Outstanding Reviewer 2020
- American Journal of Pharmaceutical Education** (4)  
**Harm Reduction Journal** (4)  
**Research in Social and Administrative Pharmacy** (2)  
**JAMA Network Open** (1); **JAMA Pediatrics** (1); **Alcohol** (1); **American Journal of Public Health** (1);  
**Pharmacology Research & Perspectives** (1); **PM&R: The journal of injury, function and rehabilitation** (1);  
**Health Services Research** (1); **Public Health Reports** (1); **Annals of Pharmacotherapy** (1); **Basic & Clinical Pharmacology & Toxicology** (1)

### Grant Review

- February 2022     **Neurological, Aging and Musculoskeletal Epidemiology (NAME) Study Section**  
NIH Early Career Reviewer (ECR)
- September 2019     **Consortium for Medical Marijuana Clinical Outcomes Research**  
Inaugural grants program manager (41 applications)

### Professional Affiliations

- 2021 – Present     **Society for Epidemiologic Research (SER)**
- 2021 – Present     **National Pain Advocacy Center (NPAC)**
- |                          |                                   |
|--------------------------|-----------------------------------|
| President 2022 – Present | Board of Directors                |
| Member 2021 – 2022       | Board of Directors                |
| Member 2020 – Present    | Science & Policy Advisory Council |
- 2020 – Present     **Facial Pain Association (FPA)**
- 2018 – Present     **International Association for the Study of Pain (IASP)**
- 2011 – Present     **International Society of Pharmacoepidemiology (ISPE)**
- |                       |   |
|-----------------------|---|
| Member 2021-2022      | Strategic Planning Committee            |
| Member 2021-2022      | ICPE 2022 Core Planning Committee       |
| Chair 2021-2022       | Publications & Communications Committee |
| Member 2020-2021      | Nominating Committee                    |
| Co-Chair 2020-2021    | Publications & Communications Committee |
| Member 2020 - Present | Social Media Subcommittee               |
| Member 2020-2021      | ICPE 2021 Core Planning Committee       |

Chair 2019-2021	Latin American Regional Interest Group (LARIG)
Co-Chair 2020	2020 Mid-Year Meeting (*Cancelled due to COVID-19)
Member 2018 – Present	Education Committee
Chair 2016 – 2017	Student Council
Member 2016 – 2017	2017 Mid-Year Planning Committee
Member 2016 – 2017	ICPE 2017 Core Planning Committee
Co-Chair 2015– 2016	Student Council
Member 2015 – 2016	Membership Committee
President 2014 – 2015	University of Florida Student Chapter

## University Service

### Faculty

2020 – 2021	Committee Member	Task Force Improve PharmD Education on BIPOC Experience
2020 – 2021	(Founding) Faculty Advisor	Organización Latina de Estudiantes de Farmacia (OLEF)
2020 – 2021	Committee Member	Pharmacy Resident Research Committee – UF Health
2019 – 2020	Faculty Lead	Social media and communications for UF CoDES
2019 – 2020	Committee Member	Pathways to Career Advancement Task Force
2019 – 2020	Committee Member	Assessment Committee – UF College of Pharmacy

### Graduate Studies

2017 - 2018	Graduate Student Member	Dean’s Leadership Council – UF College of Pharmacy
2016 - 2018	Graduate Student Member	Diversity and Inclusion Task Force – UF College of Pharmacy
2014 - 2016	Graduate Student Member	Alumni Association Committee – UF College of Pharmacy
2014 – 2015	Student President	Committee of Graduate Studies – UF College of Pharmacy
2011 - 2013	Pharmacy Student Member	National Advisory Board – UF College of Pharmacy
2011 - 2013	Pharmacy Student Member	Professionalism Committee – UF College of Pharmacy
2011	President	Student Council – UF College of Pharmacy (Jacksonville)

## TEACHING EXPERIENCE

---

### Courses Taught

Years	Institution, Program	Course #, title	Credits/Hours	Role
2019-2021 spring	University of Florida, College of Pharmacy, PharmD Program	PHA5244: Principles of Evidence-Based Practice (Co-teach with Dr. Wei-Hsuan Lo-Ciganic)	3 credits hours, >250 students (50% effort)	<b>Primary coordinator/</b> instructor
2019-2021 spring	University of Florida, College of Pharmacy, Dept. of Pharmaceutical Outcomes & Policy MS/PhD Graduate Curriculum	PHA6265: Introduction to Pharmaceutical Outcomes Research	3 credit hour, 6-10 students (4 hours)	Lecturer/ instructor
2020 Fall	University of Florida, College of Pharmacy, Dept. of Pharmaceutical Outcomes & Policy MS/PhD Graduate Curriculum	PHA6268: Pharmacoepidemiology & Drug Safety (Co-teach with Dr. Wei-Hsuan Lo-Ciganic)	3 credits hours, 20 students (50% effort)	<b>Primary coordinator/</b> instructor

2019-2021 Fall	University of Florida, College of Pharmacy, Dept. of Pharmaceutical Outcomes & Policy MS/PhD Graduate Curriculum	PHA6805: Applied Data Analysis, Interpretation, and Reporting	3 credit hours, 6-10 students (2 hours)	Lecturer/ instructor
2020 Spring	University of Florida, College of Pharmacy, PharmD Program	PHA5607L: International Pharmacy Outreach Experience	2 credit hours, 15 students (100% effort)	<b>Primary coordinator/</b> instructor
2020 Spring	University of Florida, College of Pharmacy, PharmD Program	PHA5945: Leadership in International Pharmacy Outreach Experience	1 credit hours, 5 students (100% effort)	<b>Primary coordinator/</b> instructor
2019-2021 Fall	University of Florida, College of Pharmacy, PharmD Program	PHA5226C: Patient Safety and Quality in Pharmacy	2 credit hours, >250 students (1 hour)	Lecturer/ instructor
2018 Fall	University of Florida, College of Pharmacy, PharmD Program	PHA5226C: Patient Safety and Quality in Pharmacy	2 credit hours, >250 students (100% effort)	<b>Primary coordinator/</b> instructor
2017-2018 Fall	University of Florida, College of Pharmacy, Dept. of Pharmaceutical Outcomes & Policy MS/PhD Graduate Curriculum	PHA 6805: Data Analysis and Interpretation	3 credit hours, 6-10 students (2 hours)	Lecturer/ instructor
2016-2017 Academic Year	University of Florida, Health Science Center (PharmD, MD, BSN, DVM)	Putting Families First: An Interdisciplinary Family Health Experience	15 students (8 hours)	Faculty Facilitator
2015-2017 Spring	University of Florida, College of Pharmacy, PharmD Program	PHA 5787: Pharmacotherapy V: Pain Management	3 credits hours, >250 students (8 hours)	Faculty Facilitator
2014-2017 Spring	University of Florida, College of Pharmacy, PharmD Program	PHA 5737: Drugs in Society (Co-teach with Prof. Paul Doering)	3 credits hours, 20 students (50% effort)	<b>Primary Coordinator /</b> Instructor
2014-2015 Spring	University of Florida, College of Pharmacy, PharmD Program	PHA 5742C: Professional Communications in Pharmacy Practice	2 credit hours, 35 students (20 hours)	Class Facilitator and Teaching Assistant
2014-2015 Fall	University of Florida, College of Pharmacy, PharmD Program	PHA 5226: Evidence-Based Pharmacy	4 credit hours, >250 students (30% effort)	Class Facilitator and Lead Teaching Assistant



**\*Received 2016 UF Graduate Student Teaching Award**  
**\*Received 2016 College of Pharmacy TA of the Year Award**

2013 Fall	University of Florida, College of Pharmacy, PharmD Program	PHA 5226: Evidence-Based Pharmacy	4 credit hours, >250 students (30% effort)	Teaching Assistant
--------------	---	-----------------------------------	--	--------------------

## Invited Lectures, Seminars, Tutorials, Workshop & Continuing Education Courses

### \*International

<b>Year</b>	<b>Institution, Program</b>	<b>Course #, title</b>	<b>Lecture title or role</b>
09/2021	Wisconsin Institute for Healthy Aging	“Pisando Fuerte” (Stepping On)	“Medication Management for Prevention of Falls”
*08/2021	37 <sup>th</sup> International Conference on Pharmacoepidemiology & Therapeutic Risk Management	Diversity, Equity, and Inclusion in Pharmacoepidemiology. The Role of Caste in Drug Utilization, Safety, and Therapeutic Risk Management	Plenary moderator
*08/2021	37 <sup>th</sup> International Conference on Pharmacoepidemiology & Therapeutic Risk Management	ISPE Newcomer/Early Stage Investigator Pharmacoepidemiology (Workshop)	Little “L” Leadership – Influencing Change from Where You Are”
07/2021	University of North Dakota, Counseling Program	COUN 529: Dynamics of Addiction	“Where are we in the opioid crisis in the United States?”
06/2021	Harvard University, Division of Pharmacoepidemiology	Pharmacoepidemiologic reasoning applied to the study of the opioid epidemic: Opportunities for legal epidemiology	Speaker
04/2021	University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Epidemiology	EPID 765 Methods and issues in pharmacoepidemiology	“Pharmacoepidemiologic reasoning applied to the study of the opioid epidemic”
04/2021	University of Florida, College of Medicine and College of Pharmacy	Controlled Substance Prescribing and Dispensing Policies: A Look at the History, Implications and Disparities	Speaker
04/2021	University of Florida, College of Medicine	Diversity Week - Honoring LGBTQIA+ Health Stories Panel	Panelist

*10/2020	36 <sup>th</sup> International Conference on Pharmacoepidemiology & Therapeutic Risk Management	ISPE Newcomer/Early-Stage Investigator Pharmacoepidemiology (Workshop)	“The Pharmaco-epidemiologist's Toolbox for Professional Empowerment – Personal Branding”
05/2020	Comprehensive Cancer Research Training Opportunities for Outstanding Leaders (ReTOOL)	Minority Scientist Panel Discussion	Panelist
03/2020	University of Florida, College of Pharmacy	Understanding Epidemiological Data for COVID-19 (Continuing Education)	Instructor
11/2020 04/2020 10/2019	University of Florida Center for Teaching Excellence	Effective Use of Journal Clubs to Enhance Critical Thinking Skills (Workshop)	Instructor
08/2019	53 <sup>rd</sup> Annual Meeting of the Florida Society of Health-System Pharmacy	Updates on Regulatory Guidelines and Pain Management Standards (Continuing Education)	Instructor
10/2015 10/2016 10/2017	University of Florida, College of Education, Undergraduate Curriculum	SDS 3481: Alcohol and Drug Abuse	“Opioid Use and Misuse in the United States”
*04/2016	International Society for Pharmacoepidemiology – Student Council	Use of EHR Data in Pharmacoepidemiology Research	Instructor
10/2015	University of Florida, College of Pharmacy, Department of Pharmaceutical Outcomes and Policy	Department Seminar “Regulatory, Economic, and Safety Issues of Opioid Use Management”	“Evaluating PDMP Performance: Methods, Outcomes, and Challenges”
10/2015	Circuit 3 and 8. Substance Abuse & Mental Health Program Office. Gainesville, FL.	Crisis Intervention Training for Law Enforcement	“Drugs of Abuse: Current Trends”
04/2014	University of Florida, Office of Faculty Development and Teaching Excellence	Peer2Peer workshop for teaching assistants	“Leading Small Group Discussions”

## MENTORSHIP

---

### Major Advisor & Committee Chair for Graduate Student Theses, and Dissertations

Years served	Name of Student	Program/Degree Award	Title of Thesis/Dissertation or current status
2021-Present	Theo Beltran, MPH	PhD, Epidemiology, University of North Carolina at Chapel Hill	3 <sup>rd</sup> year PhD student
2019-2021	Shailina Keshwani	MS, Pharmaceutical Outcomes & Policy, University of Florida	“Trends in Buprenorphine Prescribing Following Policies Related to Prior Authorization using Medicaid Drug Utilization data from 2012 to 2020” <b>First position:</b> PhD student at University of Florida

### Service on Master’s or Doctoral Committees

Years served	Name of Student	Program/Degree Award	Title of Thesis/Dissertation
2022-Present	Mary Figgatt	PhD, Epidemiology, University of North Carolina at Chapel Hill	3 <sup>rd</sup> year PhD student
2020-present	Ching-Yuan (Peggy) Chang	PhD, Pharmaceutical Outcomes & Policy, University of Florida	“Trajectories of Endocrine Therapy and Opioid Use, and Associated Health Outcomes among Breast Cancer Survivors” (major advisor: Wei- Hsuan Lo-Ciganic)
2021-present	Motomori Lewis	PhD, Pharmaceutical Outcomes & Policy, University of Florida	“Quality of care, analgesic use and nonadherence to hydroxyurea among Medicaid beneficiaries with sickle cell disease” (major advisor: Wei-Hsuan Lo-Ciganic)

### Advisor for Graduate Student Independent Study, Internship, Post-doctoral/Resident Projects

Years	Name of Trainee	Program	Project title
2019-2020	Samantha Brokenshire, PharmD	PGY1 Pharmacy Resident	“Impact of Opioid Restrictions During a Critical Drug Shortage Period: Interrupted Time Series for Institutional Opioid Utilization” (PMID: 32875327)
2020 – Present	Cilia Zayas, MSF, MHA	PhD student – UAMS	“The association between Medicaid expansion and prescription medications for chronic obstructive pulmonary disease: Differences by state-level rurality”
2020 - Present	Natalie Ourhaan, MBA	PharmD – Honors Project	“Utilization Trends of Amphetamine-Containing Medications Following State Opioid Restriction Laws” <b>*Top 5 student abstract at ISPOR 2021 Annual Conference</b>
2019-Present	Taylor Easey	PharmD – Honors Project	“Impact of Opioid Acute Pain Limitation Laws on Opioid Overdose Deaths”

2019-Present	Toni Tablante, Maryam Deravi	PharmD – Honors Project	“Systematic Review of Social Media Data Sources for the Evaluation of Substance Use Prevalence and Trends”
2020-Present	Jesus Muniz Oliver	PharmD – Honors Project	“Changes in utilization of febusostat in Medicaid programs after requirement of black box warning”
2020-Present	Susana Diaz	PharmD – Honors Project	“Changes in utilization of Z-drugs in Medicaid programs after requirement of black box warning”
2021-Present	Nayvel Cairo Riya Shah Alaa Abdulghani Milan Scott	PharmD	“Legal Mapping of State Naloxone Access Laws”
2019-Present	Carlos Hernandez, Aolani Chririno, Kayla Smith	PharmD	“Comparing the Current Status of State Laws of Opioid Prescribing in the United States”
2019-Present	Jerry Staret	PharmD	“Changes in Schedule II Opioid Prescriptions Dispensed by Medicaid in Following Acute Pain Opioid Restriction Laws”
2019 - Present	Ivanna Grande	PharmD	“Changes in Prescription NSAID Utilization Following Florida’s Acute Pain Restriction Policy”
2021-Present	Angelica de Jesus Sosa	PharmD	“Alcohol Mortality Outcomes and Prescription Opioid Restriction Laws”
2019-2021	Kashfaa Tasmim	Undergraduate	“Increases in County-Level Opioid Prescribing in the United States despite National Declining Rates, 2012-2018” <b>*Funded by 2019-2020 University of Florida Emerging Scholars Program</b>
2019-2021	Lilliana Thomas	Undergraduate	Study of Teen Opioid Misuse and Prevention (STOMP) Research Lab
2019-Pres	Alexis Hills	Undergraduate (Florida A&M University)	“The Prevalence of Self-Injury Among Cancer Patients: Prostate, Lung, and Colorectal Cancer” <b>*Funded by Comprehensive Cancer Research Training Opportunities for Outstanding Leaders (ReTOOL) Program</b> <b>*Winner of the 2nd best behavioral/clinical science presentation 2019 Cohort</b>

## SELECTED MEDIA COVERAGE

---

- **NSAID Prescriptions Remain Flat After Enactment of Florida Opioid Restriction Law.** Pain Medicine News (08/20/2021). Available at <https://www.painmedicineneeds.com/Policy-Management/Article/08-21/NSAID-Prescriptions-Remain-Flat-After-Enactment-of-Florida-Opioid-Restriction-Law/64258>
- **High Costs Lead Millions of Americans to Shop Abroad for Rx Drugs.** US News & World Report (06/26/2020). Available at <https://www.usnews.com/news/health-news/articles/2020-06-26/high-costs-lead-millions-of-americans-to-shop-abroad-for-rx-drugs>
- Phimister, W, host. "The Huge Problem of Health Policies with Juan M Hincapie Castillo." 21st Century Pain Solutions Podcast. Episode 81, June 2020. Available at <https://waynephimister.com/podcast/>
- **Changes in Opioid Use after Florida's Restriction Law Linked to Fewer New Users.** Pain Medicine News (05/18/2020). Available at <https://www.painmedicineneeds.com/Policy-and-Management/Article/05-20/Changes-in-Opioid-Use-After-Florida-s-Restriction-Law-Linked-to-Fewer-New-Users/58185>
- **Florida Law Tightened Opioid Prescribing, and Saw Usage Drop.** US News & World Report. (03/03/2020). Available at <https://www.usnews.com/news/health-news/articles/2020-03-03/florida-law-tightened-opioid-prescribing-and-saw-usage-drop>
- **Florida law limiting first opioid prescription linked to drop in use.** Reuters. (02/28/2020). Available at <https://www.reuters.com/article/us-health-law-opioids-florida/florida-law-limiting-first-opioid-prescription-linked-to-drop-in-use-idUSKCN20M380>
  - The New York Times (02/28/2020), Yahoo! News (02/28/2020), Medscape (03/03/2020).

## PROFESSIONAL SKILLS

---

**Languages:** Spanish (Native), English (Bilingual proficiency)

**Certificates:**

- SAS Certified Base Programmer for SAS 9 (BP065439v9)
- Policy Analysis using Interrupted Time Series (University of British Columbia UBCx – EdX)
- Longitudinal Data Analysis with R; Causal Mediation; Machine Learning (Statistical Horizons)

**Teaching Certificates**

- Fundamentals of Team-Based Learning (Team-Based Learning Collaborative)
- Great Teaching for New Faculty Certificate (UF Center for Teaching Excellence)

**Professional licensure:** Pharmacist License (PS 50790) – State of Florida

## SHORT BIO

---

Juan M. Hincapie-Castillo, Pharm.D, M.S., Ph.D. is an assistant professor of epidemiology at the University of North Carolina at Chapel Hill. Prior to joining UNC, he was an assistant professor of Pharmaceutical Outcomes & Policy at the University of Florida. He is a graduate from the University of Florida College of Pharmacy where he received the degrees of Doctor of Pharmacy (2013), Master of Science in Pharmaceutical Sciences (2017), and Ph.D. with a concentration in pharmacoepidemiology (2019). He is the recipient of the 2020 New Investigator Award from the American Association of Colleges of Pharmacy and the 2020 Emerging Leader Award from the International Society for Pharmacoepidemiology (ISPE). His research interests include the study of drug utilization and safety in pain management, the evaluation of the effects of State and Federal laws on patient outcomes (legal epidemiology), and the assessment of patient safety and quality for inpatient pain care. Juan is a consultant for the FDA's Drug Safety and Risk Management Advisory Committee (DSaRM). In 2021, he was appointed as a Research Fellow for the Center for Public Health Law Research (CPHLR) at Temple University. He currently serves as President of the Board of Directors and the Science & Policy Advisory Board for the National Pain Advocacy Center.